As Aggawal and co-workers point out, its TNF-α inhibition alone justifies the cost of this development, since current TNF-α inhibitors are used not only for IBD, but also for osteoarthritis, psoriasis, and ankylosis, at a cost of $15,000–$20,000 per person per year [31]. The gene discussed is TNF; the disease is irritable bowel syndrome.